These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 38753697)

  • 21. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
    Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
    Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
    Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
    Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
    Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
    Yamamoto N; Mera T; Märten A; Hochmair MJ
    Adv Ther; 2020 Feb; 37(2):759-769. PubMed ID: 31863283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
    JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis.
    Yi L; Fan J; Qian R; Luo P; Zhang J
    Int J Cancer; 2019 Jul; 145(1):284-294. PubMed ID: 30613959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis.
    Xing P; Mu Y; Hao X; Wang Y; Li J
    Clin Transl Oncol; 2019 Oct; 21(10):1424-1431. PubMed ID: 30864019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control.
    Jeon HL; Kwak M; Kim S; Yu HY; Shin JY; Jung HA
    Sci Rep; 2024 Jun; 14(1):14659. PubMed ID: 38918528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib.
    Wang H; Pan R; Zhang X; Si X; Wang M; Zhang L
    Thorac Cancer; 2020 Mar; 11(3):594-602. PubMed ID: 31943845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study.
    Cao Y; Qiu X; Xiao G; Hu H; Lin T
    PLoS One; 2019; 14(8):e0221575. PubMed ID: 31442277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M
    Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation.
    Wang S; Yan B; Zhang Y; Xu J; Qiao R; Dong Y; Zhang B; Zhao Y; Zhang L; Qian J; Lu J; Zhao R; Han B
    Int J Cancer; 2019 Jun; 144(11):2880-2886. PubMed ID: 30474188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
    Wu YL; Ahn MJ; Garassino MC; Han JY; Katakami N; Kim HR; Hodge R; Kaur P; Brown AP; Ghiorghiu D; Papadimitrakopoulou VA; Mok TSK
    J Clin Oncol; 2018 Sep; 36(26):2702-2709. PubMed ID: 30059262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Mitsuya S; Tsuruoka K; Kanaoka K; Funamoto T; Tsuji H; Matsunaga N; Nakamura T; Tamura Y; Imanishi M; Ikeda S; Fujisaka Y; Goto I; Imagawa A
    Anticancer Res; 2021 Oct; 41(10):5137-5145. PubMed ID: 34593465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
    Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
    Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.